CTOs on the Move

Vitality Biopharma

www.vitality.bio

 
Vitality has developed a new class of cannabinoid prodrugs (cannabosides), which enable selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable potent local therapeutic effects while reducing or avoiding the systemic delivery of THC to the brain. Currently, the psychoactivity of THC limits the dose of cannabinoids that can be used for treatment of pain and inflammation. Studies have shown that the cannabinoid system is a potent mediator of pain relief and inflammation, as studies have shown that cannabinoid drugs can in some cases be far more potent than opiates for pain relief, and far ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vitality.bio
  • 1901 Avenue of the Stars 2nd Floor
    Los Angeles, CA USA 90067
  • Phone: 530.231.7800

Executives

Name Title Contact Details

Similar Companies

Nystrom & Associates

Nystrom & Associates Here at Nystrom & Associates, we know that you want to feel confident and excited about life. Were here to help!

Strategyx

Strategyx is a Somerville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BVI

Beaver-Visitec International (BVI) is a highly regarded ophthalmic device manufacturer offering a broad range of single use instruments & custom procedure packs

FosunPharmaUSA

NOW AVAILABLETobramycin for Injections, USPOur ProductsCovid-19 Detection Kit and Extraction ReagentLearn MoreSpecialty Pharmaceutical Injectables & Ophthalmics Our ProductsIn The NewsFosun Partners with The National Children’s Cancer SocietyLearn More...

Santen

At Santen, we`re innovating therapies to improve the quality of life for patients worldwide. Our single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a global company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Our clinical development network now spans three continents, with centers in EMEA (Europe, the Middle East and Africa), Japan, and the United States.